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decay is not the only mechanism under-
lying acquired oncogene dependence, 
and engaging these other mechanisms 
may require longer-term drug exposure 
(Figure 1Bc). Hence, it remains to be seen 
whether a “short, sharp shock” or “staying 
the course” proves the best strategy for 
drug delivery.
More generally, the important and 
fascinating observations of Sharma et 
al. underscore once again (as if this 
were even necessary) the critical impor-
tance of identifying which of the legion of 
mutations in human cancers is respon-
sible for maintenance of the established 
tumor. Tumors accumulate much muta-
tional clutter—bottlenecks that once 
passed are thenceforth irrelevant for 
further tumor maintenance, collateral 
havoc borne of telomere erosion, back-
ground noise that clones out with the 
tumor, bystanders swept up by neigh-
boring amplifications or deletions, and 
weakly advantageous traits contingent 
upon the platform of oncogenic engines 
that buttress tumor maintenance. The 
real trick is to work out who is pulling 
the levers and pressing the buttons that 
keep the established tumor going and 
not get sidetracked into endless cata-
loging of epiphenomena. Sharma et al. 
show that evolution has handed us a 
great gift for cancer treatment—so long 
as we stay on target.
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Mouse models that faithfully recapitulate human cancers are indispensable tools for studying the molecular mechanisms of 
tumorigenesis and testing potential anticancer therapies. In this issue of Cancer Cell, Derksen et al. describe a new mouse 
model that mimics multiple features of invasive lobular carcinoma of the breast (ILC), a histological subtype of human breast 
cancer for which no mouse model currently exists. This model further reveals an important causal link between E-cadherin 
loss and tumor initiation and metastasis and, in doing so, provides a valuable entrée into the tumor-suppressive functions of 
E-cadherin as well as the molecular underpinnings of ILC.Over the past two decades, the devel-
opment of improved mouse models for 
human cancers has made important 
contributions to our understanding of 
this set of diseases. By engineering 
mice to contain specific genetic lesions 
found in human cancers, it has been 
possible to address the causal relation-
ship between individual genes and the 
disease phenotype. Furthermore, mice 
that develop malignancies that faith-
fully recapitulate their human counter-
parts provide—at least in theory—more 
appropriate physiological systems in 
which to test candidate antineoplastic 
drugs. Indeed, an array of mouse mod-
els now exists in which the modulation of cancer cell November 2006 one or more genes altered in a particular 
human cancer gives rise to a malignan-
cy in mice that resembles that cancer 
at both the histological and molecular 
levels (Holland, 2004). Moreover, as a 
first step toward fulfilling their promise, 
these models are now being utilized for 
the validation and testing of therapies 
(Sharpless and Depinho, 2006).
Given the success of genetically 
engineered mouse models to date, an 
important next step will be the creation of 
refined models that accurately reflect the 
diverse pathologies of human cancers. In 
breast cancer, for instance, the majority of 
patients present with invasive ductal car-
cinoma (IDC), whereas ?10% of patients present with a histologically distinct form 
of the disease, termed invasive lobular 
carcinoma (ILC). Beyond their morpho-
logic distinctions, these tumor types 
also differ at the molecular level. One 
particularly prominent difference is that 
ILCs typically lose expression of the cell 
adhesion molecule E-cadherin, whereas 
IDCs retain its expression. ILC and IDC 
also exhibit differences in their biological 
behavior, including their patterns of meta-
static spread. To date, however, there has 
been no mouse model that recapitulates 
the unique features of ILC, a fact that has 
impeded research into this disease.
A study by Derksen et al. in this 
issue now addresses this shortcom-347
	 p r e v i e w sFigure 1. Similarities between a mouse model for invasive lobular carcinoma, mILC, and its human 
counterpart, hILC
mILC: Conditional deletion of E-cadherin alone in the mammary epithelium is thought to lead to p53-
dependent cell death, whereas conditional deletion of both E-cadherin and p53 leads to invasive 
lobular carcinoma (ILC). The morphological characteristics of precursor lesions are unknown. mILCs 
have an increased incidence of metastasis compared to tumors lacking p53 alone. hILC: Loss of E-
cadherin—thought to occur through somatic mutation or LoH—is found in both LCIS and ILC, though 
it is unclear whether LCIS is a precursor of ILC. The pattern of metastasis in ILC differs significantly from 
IDC, with metastases to the GI tract and ovary occurring more frequently in ILC compared to IDC. The 
majority of human ILCs are thought to express wild-type p53, though some tumors may lose the p53 
locus. In the presence of functional p53, increased expression of antiapoptotic genes may suppress cell 
death downstream of e-cadherin loss. Differences between mILC and hILC are shown in red.ing while simultaneously supporting a 
causal link between E-cadherin loss 
and the development of ILC (Derksen 
et al., 2006). In this study, the authors 
have created a mouse model for breast 
cancer driven by the conditional deletion 
of floxed p53 and/or E-cadherin alleles 
in the mammary gland and skin via 
expression of Cre recombinase under 
the control of the Keratin 14 (K14) pro-
moter. While mice whose mammary epi-
thelial cells lacked p53 alone developed 
mammary carcinomas, the latency was 
long (330 days), and tumors exhibited a 
low frequency of metastasis. Given the 
documented role of E-cadherin in tumor 
cell invasion, the authors next tested the 
effect of adding E-cadherin deletion to 
p53 deletion on tumor formation and 
metastasis. Interestingly, they found that 
mice lacking both p53 and E-cadherin 
developed mammary tumors significant-
ly faster than mice lacking p53 alone. In 
addition, loss of E-cadherin appeared 
348 to be selected for early in the course 
of tumorigenesis. Together, their find-
ings suggest that E-cadherin loss may 
contribute to both tumor initiation and 
progression.
However, the most notable finding 
of this study was that tumors forming 
in mice whose mammary epithelial 
cells lacked both E-cadherin and p53 
had a histological appearance highly 
reminiscent of human ILC. Specifically, 
cells from these tumors were small 
and uniform, were oriented in a char-
acteristic “single file” arrangement, and 
had invaded the surrounding stroma. 
Notably, tumors lacking both p53 and 
E-cadherin metastasized more fre-
quently than those lacking p53 alone. 
From these data, the authors conclude 
that mammary tumors arising in mice in 
the context of p53 and E-cadherin loss 
frequently mimic the cellular and histo-
logical features of human ILC, and term 
their model “mouse ILC” (mILC).How well does this new model 
recapitulate human ILC? In several 
respects—including histological pattern, 
cellular morphology, lack of E-cadherin 
expression, and Her2/neu negativity—
this model is a dead ringer for its human 
counterpart. In addition, mILC metas-
tasizes to analogous sites as seen in 
women, including the lymphatics, lungs, 
liver, gastrointestinal tract, and peritone-
um (Figure 1). Nevertheless, mILC dif-
fers from human ILC in several important 
ways. First, mammary tumors arising in 
mice due to loss of p53 and E-cadherin 
are estrogen receptor (ER) and proges-
terone receptor (PR) negative, whereas 
the vast majority of human ILCs are ER 
and PR positive. However, as most mam-
mary tumors induced in mice are ER and 
PR negative, this may reflect a general 
shortcoming of the mouse as a model 
for ER-positive human breast cancer 
rather than a specific problem with this 
model. The metastatic behavior of these 
tumors also reveals differences between 
the mouse model and human disease. 
Whereas the overall incidence of metas-
tasis is similar between ILC and IDC 
in humans (Arpino et al., 2004), mILC 
tumors have a markedly higher meta-
static potential than tumors wild-type for 
E-cadherin.
On other points, the jury is out. For 
example, the formation of mILC in the 
mouse requires loss of both E-cadherin 
and p53, a potential concern given that 
p53 mutation is reportedly less com-
mon in human ILC than IDC (Arpino et 
al., 2004). Nevertheless, up to 25% of 
hILC may express mutant p53, and more 
recent studies suggest that a substantial 
fraction of human ILCs may harbor chro-
mosomal losses encompassing the p53 
locus (Mohsin et al., 2005; Stange et al., 
2006). One intriguing possibility is that 
the mouse model presented by Derksen 
et al. recapitulates that subset of human 
ILCs that have lost p53 function, either 
through mutation or chromosomal loss, 
whereas other subsets of hILC may exist 
that retain p53 function. If this is the 
case, it is possible that this latter subset 
of tumors may contain genetic altera-
tions more commonly found in human 
ILC, such as bcl-2 overexpression, that 
substitute for p53 loss in synergizing with 
the loss of E-cadherin (Papadimitriou et 
al., 1997). Gaining a clearer understand-
ing of the status of p53 in human ILC 
will be critical for resolving whether the 
mouse model falls short—or provides 
novel insights—on these points.cancer cell November 2006
	 p r e v i e w sImportantly, the findings of Derksen 
et al. constitute the first demonstration in 
mice of a causal link between E-cadherin 
loss and tumor formation. Given the 
wealth of data from cell culture studies 
and human patient samples implicating 
E-cadherin in tumor progression, this is 
a central finding that establishes E-cad-
herin as a bona fide tumor suppressor. 
Notably, while E-cadherin loss is thought 
to be a critical step in the process of 
epithelial-to-mesenchymal transition 
(EMT), the extent to which EMT per se 
is involved in tumor progression remains 
unclear. For example, the transcription-
al repressor Snail has been shown to 
downregulate E-cadherin as well as pro-
mote both EMT and tumor progression 
in a conditional mouse model for HER2/
neu-induced breast cancer (Moody et 
al., 2005). In contrast, E-cadherin loss 
in the model described by Derksen et al. 
does not by itself lead to a frank mesen-
chymal phenotype. This suggests that, at 
least in this context, E-cadherin loss can 
promote tumorigenesis independently of 
its contribution to EMT.
Another puzzling feature of this dis-
ease has been the uncertain relationship 
between ILC and lobular carcinoma in 
situ (LCIS). Women with LCIS are at sub-
stantially increased risk for developing 
breast cancer both in the same breast 
in which the LCIS was identified and in 
the opposite breast. As such, whether 
LCIS represents a precursor lesion to 
ILC, or merely a marker of increased 
risk, continues to be a matter of debate. cancer cell November 2006 
As one looks back over past decades, or 
for that matter, past centuries, scientific 
progress, though remarkable, has been 
limited by tools and the ways insights 
have been shared. Three recent papers 
by the Golub and Armstrong groups 
(Lamb et al., 2006; Hieronymus et al., 
Accelerating drug dis
The possibility that experimental data fro
generally outside the realm of cancer bio
experiments using a set of known membe
other unrelated experiments. The potenti
exact initial conditions. The limitations wIt is notable, therefore, that despite the 
markedly increased risk of mILC in mice 
in which E-cadherin and p53 have been 
deleted in the mammary epithelium, 
classic LCIS lesions are not found. This 
raises the important possibility that LCIS 
is not a precursor lesion for ILC, or that 
mILC models a form of ILC that does not 
pass through an LCIS phase.
Finally, beyond its important 
mechanistic implications, this study by 
Derksen et al. is equally significant for 
its establishment of a faithful model for 
human ILC where none existed before. 
This accomplishment represents a 
significant step forward in the effort 
to accurately model human cancers in 
mice. As they constitute only 10%–15% 
of all breast cancers, lobular carcino-
mas are likely to differ from ductal 
carcinomas with respect to their etiol-
ogy, biology, and response to therapy. 
As such, the availability of this model 
holds significant promise for improving 
our ability to understand and treat this 
type of breast cancer. Undoubtedly, it 
will be important to continue refining 
this model to more precisely incorpo-
rate the molecular alterations found 
in human ILC, as these become eluci-
dated. Ultimately, such models should 
prove useful for testing therapeutic reg-
imens targeted specifically against ILC 
and in that manner improve the clinical 
management of this disease. This hope, 
if realized, would constitute the most 
meaningful validation of all for this—or 
any—mouse model.2006; Wei et al., 2006) describe a pro-
cess, a tool, and even better, examples 
of how that tool functions that suggest 
an opportunity which, if fully implement-
ed, has the potential to truly change the 
speed and efficiency of drug discovery.
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covery: Open source ca
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cies of cancer biology and drug discov-
ery is the full extent to which we fly blind. 
From the size of textbooks and the com-
plexity of pathway diagrams it is hard 
to recognize that for virtually all cancer 
processes we do not have confidence in 
the complete “parts list” of components 
ncer cell biology?
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